Abstract
In the past years, six monogenic forms of Parkinson disease have clearly been associated with this movement disorder. The most frequent forms are LRRK2- and Parkin-associated Parkinson disease. Currently, a genetic diagnosis does not change the therapy, the genes involved in genetic Parkinson disease help to understand the underlying pathophysiologic mechanisms of Parkinson disease. Beside the overview of the molecular-genetic basis, we give a review about genetic testing, pharmacological and other multidisciplinary treatment options.
MeSH terms
-
Antiparkinson Agents / therapeutic use*
-
Combined Modality Therapy / methods
-
Dance Therapy
-
Deep Brain Stimulation*
-
Genetic Predisposition to Disease
-
Genetic Testing
-
Genetic Therapy
-
Humans
-
Intracellular Signaling Peptides and Proteins / genetics
-
Leucine-Rich Repeat Serine-Threonine Protein Kinase-2
-
Music Therapy
-
Oncogene Proteins / genetics
-
Parkinson Disease / diagnosis
-
Parkinson Disease / drug therapy
-
Parkinson Disease / genetics*
-
Parkinson Disease / therapy*
-
Physical Therapy Modalities
-
Protein Deglycase DJ-1
-
Protein Kinases / genetics
-
Protein Serine-Threonine Kinases / genetics
-
Psychotherapy
-
Relaxation Therapy
-
Ubiquitin-Protein Ligases / genetics
-
alpha-Synuclein / genetics
Substances
-
Antiparkinson Agents
-
Intracellular Signaling Peptides and Proteins
-
Oncogene Proteins
-
alpha-Synuclein
-
Ubiquitin-Protein Ligases
-
parkin protein
-
Protein Kinases
-
LRRK2 protein, human
-
Leucine-Rich Repeat Serine-Threonine Protein Kinase-2
-
PTEN-induced putative kinase
-
Protein Serine-Threonine Kinases
-
PARK7 protein, human
-
Protein Deglycase DJ-1